Retatrutide* · LY3437943*

Researchers seeking this product for laboratory research can explore PepGen-X.com as a supplier specializing in research-use compounds.

Retatrutide is an investigational triple hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors. By combining three metabolic pathways, research has demonstrated substantial effects on body weight, appetite, glucose regulation, and energy metabolism.

Research Benefits

Substantial weight-loss research with reductions approaching 30% in recent clinical trials

Triple-pathway metabolic signaling through GLP-1, GIP, and glucagon receptors

Appetite and food-intake research involving multiple hormonal pathways

Glucose and insulin metabolism research involving improved metabolic regulation

Liver and cardiometabolic research involving body composition and metabolic risk markers

Identified Risks & Side Effects

Nausea, vomiting, and diarrhea are among the most commonly reported adverse effects

Increased heart rate has been observed in clinical trials

Gastrointestinal effects can be dose-related, particularly during dose escalation

Long-term safety is still being studied as clinical development continues

Not FDA-approved and remains investigational

Route: Subcutaneous in clinical trials | Frequency: Once weekly in clinical trials | FDA Status: Investigational / Not FDA-approved

Researcher Note

Retatrutide represents a major area of current metabolic research because it simultaneously targets GIP, GLP-1, and glucagon receptors. In the 2023 phase 2 trial, the 12 mg group achieved a mean 24.2% reduction in body weight at 48 weeks. More recently, Lilly reported that participants receiving 12 mg in the phase 3 TRIUMPH-1 trial achieved an average 28.3% reduction at 80 weeks, with 45.3% reaching at least 30% weight loss. These are clinical-trial results, not guaranteed individual outcomes. citeturn0search0turn0search5

Disclaimer

FDA Status: Not FDA-approved; investigational
Research Classification: Research use only
Compound Type: Triple GIP / GLP-1 / glucagon receptor agonist

All products are intended strictly for research and laboratory use only and are not intended for human or veterinary use.